Oragenics (OGEN) reports immediate-vesting stock option grants to director

Rhea-AI Filing Summary

Oragenics Inc. reported that director Natasha Giordano received two stock option awards under the company’s 2021 Equity Incentive Plan on December 11, 2025. One non-employee director option covers 38,320 shares of common stock at an exercise price of $1.03, granted as an initial equity award upon her appointment to the board, and it vests immediately. A second option covers 125,000 shares at an exercise price of $0.93, also under the non-employee director compensation program, and it vests immediately as well. Both option grants are exercisable from December 11, 2025 and expire on December 11, 2035, and are held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Giordano Natasha

(Last) (First) (Middle)

1990 MAIN STREET, SUITE 750

(Street)

SARASOTA FL 34236

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ORAGENICS INC [ OGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Employee Director Option (Right to Buy)(1)	$1.03	12/11/2025		A		38,320(1)		12/11/2025(1)	12/11/2035	Common Stock	38,320	$0	38,320(1)	D
Non-Employee Director Option (Right to Buy)(2)	$0.93	12/11/2025		A		125,000(2)		12/11/2025(2)	12/11/2035	Common Stock	125,000	$0	125,000(2)	D

Explanation of Responses:

1. Represents an initial equity award upon appointment to the Company's board of directors (the "Board") of options pursuant to the non-employee director compensation program to purchase shares of the Company's common stock under the Company's 2021 Equity Incentive Plan that vests immediately. The option exercise price is the Company's closing price on the date immediately prior to the reporting person's appointment to the Company's Board. The Board granted the options on December 11, 2025.

2. Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant.

	/s/ Julio C. Esquivel as Attorney-In-Fact for Natasha Giordano	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Oragenics (OGEN) report in this Form 4?

The Form 4 reports that director Natasha Giordano received two stock option awards under Oragenics’ 2021 Equity Incentive Plan on December 11, 2025, both relating to options to buy the company’s common stock.

How many Oragenics (OGEN) stock options did director Natasha Giordano receive and at what prices?

Natasha Giordano received one option covering 38,320 shares at an exercise price of $1.03 per share and a second option covering 125,000 shares at an exercise price of $0.93 per share.

When do the Oragenics (OGEN) director stock options granted to Natasha Giordano vest and expire?

Both stock option awards to Natasha Giordano vest immediately. They are exercisable from December 11, 2025 and have an expiration date of December 11, 2035.

Under which plan were Natasha Giordano’s Oragenics (OGEN) options granted?

The options were granted under Oragenics’ 2021 Equity Incentive Plan, with one award described as an initial equity award upon appointment to the board and the other as part of the non-employee director compensation program, as amended.

What is the nature of Natasha Giordano’s relationship to Oragenics (OGEN) in this filing?

The filing identifies Natasha Giordano as a director of Oragenics Inc., and the reported transactions relate to her equity compensation as a non-employee director.